Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING
GLOBETECH PUBLISHING
PZ HTL SA

Highly Sensitive Prostate Cancer Imaging Using Small Prostate-Specific Membrane Antigen Molecules

By BiotechDaily International staff writers
Posted on 18 Mar 2013
Two unique radiolabeled small molecules targeting prostate-specific membrane antigen (PSMA) have excellent possibilities for additional development as diagnostic and therapeutic radiopharmaceutical agents. The imaging agents, 123I-MIP-1072 and 123I-MIP-1095, were shown to have a high sensitivity of lesion detection in soft tissue, bone, and the prostate gland with nominal retention in nontarget tissue.

An estimated 238,500 men will be diagnosed with prostate cancer in 2013, and 29,700 will die from the disease. Effective staging and diagnosis of prostate cancer is critical to determining the correct patient management. Patients with localized disease may benefit from a curative treatment, while those with bone metastases are usually treated with systemic therapy.

“Current imaging techniques have limitations in diagnosing and staging prostate cancer. New imaging approaches, including the radiolabeled small molecules 123I-MIP-1072 and 123I-MIP-1095, may assess disease status more accurately,” said John J. Babich, PhD, from Molecular Insight Pharmaceuticals, Inc. (Cambridge, MA, USA), and lead author of the article, which was published March 2013 in the Journal of Nuclear Medicine (JNM). “Improved imaging approaches could better facilitate the selection of optimal treatment and improve patient outcomes.”

Separate studies were conducted as part of phase 1 trials under an investigational new drug (IND) application to measure the potential effectiveness of the small molecules in diagnosing and staging prostate cancer. In the first study, seven patients with validated prostate cancer were administered doses of 123I-MIP-1072 and 123I-MIP-1095 two weeks apart. In the second study, six healthy volunteers received 123I-MIP-1072 only. Whole body planar imaging and single photon emission computed tomography (SPECT)/computed tomography (CT) were performed for each group, and pharmacokinetics, tissue distribution, excretion, safety, and organ radiation dose were studied.

Both 123I-MIP-1072 and 123I-MIP-1095 visualized lesions in soft tissue, bone and the prostate gland as early as one to four hours after injection. The imaging agents cleared the blood in a biphasic manner; however, clearance of 123I-MIP-1072 was approximately five times faster, resulting in a higher lesion-to-background ratio as compared to 123I-MIP-1095. The largest organ-absorbed radiation doses for 123I-MIP-1072 were to the urinary bladder, salivary glands, and kidneys; for 123I-MIP-1095 the absorbed doses to the salivary glands, kidneys, and thyroid were the largest. Both imaging agents were well tolerated by the study participants.

As a result of the phase 1 findings, 123I-MIP-1072 was assessed as a diagnostic agent in subsequent clinical trials on the basis of its higher lesion-to-background ratios and prolonged tumor retention. 123I-MIP-1095 will be clinically examined for radiotherapy for metastatic prostate cancer as the 131I-labeled analog.

“A more accurate method of imaging prostate cancer and prostate cancer metastases would significantly impact the clinical management of men with prostate cancer. This would provide greater certainty as to the presence and extent of disease during the course of the patient’s treatment,” said Dr. Babich. “Data indicate that PSMA is an excellent target for molecular imaging of prostate cancer and that radiolabeled small molecules, which bind PSMA with high affinity, can localize prostate cancer anywhere in the body. The use of SPECT for molecular imaging could represent a significant advance in cancer evaluation.”

Related Links:

Molecular Insight Pharmaceuticals



Channels

Genomics/Proteomics

view channel
Image: Biopsy of small bowel showing celiac disease manifested by blunting of villi, crypt hyperplasia, and lymphocyte infiltration of crypts (Photo courtesy of Wikimedia Commons).

Reduced Elafin Levels Associated with Celiac Disease Bowel Inflammation

Levels of the enzyme elafin, an endogenous serine protease inhibitor, were lower in the small intestinal epithelium of patients with active celiac disease (CD) as compared to similar tissue from control patients.... Read more

Drug Discovery

view channel

Retinoic Acid Prevents Precancerous Breast Cells from Progressing to Full-Blown Cancer

Retinoic acid, a derivative of vitamin A, was found to prevent pre-cancerous breast cells from progressing to full-blown cancer but did not have any effect on breast tumor cells. Investigators at Thomas Jefferson University (Philadelphia, PA, USA) worked with a novel breast cancer model that had been developed by treating... Read more

Biochemistry

view channel

Mitochondrial Cause of Aging Can Be Reversed

Researchers have found a cause of aging in lab animals that can be reversed, possibly providing an avenue for new treatments for age-related diseases including type 2 diabetes, cancer, muscle wasting, and inflammatory diseases. The researchers plan to begin human trials late 2014. The study, which was published December... Read more

Therapeutics

view channel

Cytokine Identified That Causes Mucositis in Cancer Therapy Patients

The action of the cytokine interleukin 1-beta (IL-1beta) has been found to underlie the onset of mucositis, a common, severe side effect of chemotherapy and irradiation of cancer patients. Mucositis occurs as a result of cell death in reaction to chemo- or radiotherapy. The mucosal lining of the mouth becomes thin, may... Read more

Business

view channel

Analytical Sciences Trade Fair Declared a Rousing Success

Organizers of this year's 24th "analytica" biosciences trade fair have reported significant increases in both the number of visitors and exhibitors compared to the 2012 event. The analytica trade fair for laboratory technology, analysis, and biotechnology has been held at the Munich (Germany) Trade Fair Center every... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.